SG11201403429YA - Contrast agent for imagining myocardial perfusion - Google Patents

Contrast agent for imagining myocardial perfusion

Info

Publication number
SG11201403429YA
SG11201403429YA SG11201403429YA SG11201403429YA SG11201403429YA SG 11201403429Y A SG11201403429Y A SG 11201403429YA SG 11201403429Y A SG11201403429Y A SG 11201403429YA SG 11201403429Y A SG11201403429Y A SG 11201403429YA SG 11201403429Y A SG11201403429Y A SG 11201403429YA
Authority
SG
Singapore
Prior art keywords
imagining
contrast agent
myocardial perfusion
perfusion
myocardial
Prior art date
Application number
SG11201403429YA
Inventor
Martin Johansson
Original Assignee
Respiratorius Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respiratorius Ab filed Critical Respiratorius Ab
Publication of SG11201403429YA publication Critical patent/SG11201403429YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201403429YA 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion SG11201403429YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579113P 2011-12-22 2011-12-22
SE1151249 2011-12-22
PCT/SE2012/051421 WO2013095273A1 (en) 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion

Publications (1)

Publication Number Publication Date
SG11201403429YA true SG11201403429YA (en) 2014-07-30

Family

ID=48668967

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403429YA SG11201403429YA (en) 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion

Country Status (16)

Country Link
US (2) US9295738B2 (en)
EP (1) EP2793952B1 (en)
JP (1) JP6140187B2 (en)
KR (1) KR101931792B1 (en)
CN (1) CN104114191A (en)
AU (1) AU2012354223B2 (en)
BR (1) BR112014015124A2 (en)
CA (1) CA2859773C (en)
ES (1) ES2687234T3 (en)
HK (1) HK1201459A1 (en)
IL (1) IL233219A (en)
MX (1) MX356258B (en)
RU (1) RU2629840C2 (en)
SG (1) SG11201403429YA (en)
WO (1) WO2013095273A1 (en)
ZA (1) ZA201405199B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9955876B2 (en) * 2016-09-08 2018-05-01 Raul Chirife Device and method for assessment of left ventricular ejection fraction and other parameters of cardiac performance
CN107233585B (en) * 2017-06-09 2021-01-22 四川大学华西医院 Application of berberine or derivatives thereof in preparation of myocardial perfusion imaging agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7932272B2 (en) * 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
US7824659B2 (en) * 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
ES2432070T3 (en) * 2009-02-24 2013-11-29 Respiratorius Ab Novel bronchodilator diazaheteroaryls

Also Published As

Publication number Publication date
CA2859773C (en) 2020-09-01
JP6140187B2 (en) 2017-05-31
AU2012354223B2 (en) 2017-03-16
BR112014015124A2 (en) 2017-06-13
CN104114191A (en) 2014-10-22
KR20140107411A (en) 2014-09-04
KR101931792B1 (en) 2019-03-13
HK1201459A1 (en) 2015-09-04
ZA201405199B (en) 2015-12-23
IL233219A (en) 2016-08-31
RU2629840C2 (en) 2017-09-04
IL233219A0 (en) 2014-08-31
EP2793952A4 (en) 2015-09-09
US20140341808A1 (en) 2014-11-20
EP2793952B1 (en) 2018-06-13
RU2014125849A (en) 2016-02-10
AU2012354223A1 (en) 2014-07-03
US9295738B2 (en) 2016-03-29
JP2015500873A (en) 2015-01-08
MX356258B (en) 2018-05-16
ES2687234T3 (en) 2018-10-24
MX2014007491A (en) 2015-02-17
US9687565B2 (en) 2017-06-27
EP2793952A1 (en) 2014-10-29
WO2013095273A1 (en) 2013-06-27
CA2859773A1 (en) 2013-06-27
US20160101195A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AP3634A (en) Active compound combinations
ZA201403090B (en) Tropicalizing agent
EP2611291A4 (en) Perfusion composition
PT2688413T (en) Active compound combinations
HK1246793A1 (en) 2-acylaminothiazole compound crystals
HK1182995A1 (en) Compound body
HK1173368A1 (en) Pigmentation-preventing or-ameliorating agent
GB2525835B (en) Pharmaceutical agent
EP2787050A4 (en) Lecithin-organogel-forming agent
HK1201459A1 (en) Contrast agent for imagining myocardial perfusion
ZA201304156B (en) Imaging agents
TWI562734B (en) Sense-improving agent
EP2764870A4 (en) Sense-improving agent
EP2666460A4 (en) Skin-whitening agent containing 3-hydroxy-2-pyrone
PL2709454T3 (en) Active compound combinations
GB201116152D0 (en) Cannabinoid-2-receptor agonists
ZA201400527B (en) Encapsulated benefit agent
ZA201400726B (en) Anticancer agent
EP2640832A4 (en) New ethiological agent
AU4553P (en) WES04 Westringia fruticosa
GB2489064B (en) Monitor
GB201101679D0 (en) Self stir
ZA201209781B (en) Cooling agent
GB201108234D0 (en) Pharmaceutical agent
AU2011905352A0 (en) Imaging agents